Phase 3 results announced for an all oral, - sofosbuvir-based regimen for the treatment of hepatitis C - in patients co-infected with HIV Gilead Sciences, Inc. has announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue inhibitor sofosbuvir for the treatment of chronic hepatitis C virus ... (more)
http://www.medilexicon.com/medicalnews.php?newsid=268345
http://www.medilexicon.com/medicalnews.php?newsid=268345
No comments:
Post a Comment